GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heron Therapeutics Inc (NAS:HRTX) » Definitions » Shiller PE Ratio

HRTX (Heron Therapeutics) Shiller PE Ratio : (As of Apr. 11, 2025)


View and export this data going back to 1987. Start your Free Trial

What is Heron Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Heron Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Heron Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heron Therapeutics Shiller PE Ratio Chart

Heron Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Heron Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Heron Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Heron Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heron Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's Shiller PE Ratio falls into.


;
;

Heron Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Heron Therapeutics's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Heron Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.02/133.1571*133.1571
=0.020

Current CPI (Dec. 2024) = 133.1571.

Heron Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.700 99.621 -0.936
201506 -0.740 100.684 -0.979
201509 -0.630 100.392 -0.836
201512 -0.870 99.792 -1.161
201603 -0.920 100.470 -1.219
201606 -1.170 101.688 -1.532
201609 -1.240 101.861 -1.621
201612 -1.220 101.863 -1.595
201703 -1.000 102.862 -1.295
201706 -0.800 103.349 -1.031
201709 -0.770 104.136 -0.985
201712 -1.100 104.011 -1.408
201803 -0.810 105.290 -1.024
201806 -0.540 106.317 -0.676
201809 -0.490 106.507 -0.613
201812 -0.630 105.998 -0.791
201903 -0.800 107.251 -0.993
201906 -0.630 108.070 -0.776
201909 -0.420 108.329 -0.516
201912 -0.650 108.420 -0.798
202003 -0.570 108.902 -0.697
202006 -0.610 108.767 -0.747
202009 -0.640 109.815 -0.776
202012 -0.680 109.897 -0.824
202103 -0.580 111.754 -0.691
202106 -0.620 114.631 -0.720
202109 -0.510 115.734 -0.587
202112 -0.540 117.630 -0.611
202203 -0.630 121.301 -0.692
202206 -0.550 125.017 -0.586
202209 -0.380 125.227 -0.404
202212 -0.170 125.222 -0.181
202303 -0.270 127.348 -0.282
202306 -0.350 128.729 -0.362
202309 -0.170 129.860 -0.174
202312 -0.050 129.419 -0.051
202403 -0.020 131.776 -0.020
202406 -0.060 132.554 -0.060
202409 -0.030 133.029 -0.030
202412 0.020 133.157 0.020

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Heron Therapeutics  (NAS:HRTX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Heron Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Heron Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Heron Therapeutics Business Description

Traded in Other Exchanges
Address
4242 Campus Point Court, Suite 200, San Diego, CA, USA, 92121
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Executives
William P Forbes officer: EVP, Chief Development Officer C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Adam Morgan other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Ira Duarte officer: EVP, Chief Financial Officer 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Craig A Collard director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kevin Kotler director C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Velan Capital Master Fund Lp other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
David Efraim Rosen other: See Footnote 1 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Rubric Capital Management Lp other: See Footnote 1 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Balaji Venkataraman other: See Footnote 2 FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Kimberly Manhard director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Craig A Johnson director C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Waage Christian director RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121